Kerberos

Kerberos BioPharma is a German biotechnology company focused on the development of next-generation multi-specific antibodies for cancer immunotherapy. Based in the Martinsried biotech hub near Munich, the company utilizes its proprietary Kerberos platform to engineer bispecific molecules designed to recruit and activate T-cells against tumor cells. Their technology aims to optimize the potency and safety of T-cell engagers, addressing current limitations in the treatment of solid tumors and hematological cancers. By leveraging advanced protein engineering, Kerberos BioPharma is building a pipeline of innovative therapeutic candidates intended to provide more effective options for patients with difficult-to-treat malignancies.